Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caramori, M. L.
Right arrow Articles by Gross, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caramori, M. L.
Right arrow Articles by Gross, J. L.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 52:3010-3013, 2003
© 2003 by the American Diabetes Association, Inc.

Brief Genetics Report

The Human Peroxisome Proliferator-Activated Receptor {gamma}2 (PPAR{gamma}2) Pro12Ala Polymorphism Is Associated With Decreased Risk of Diabetic Nephropathy in Patients With Type 2 Diabetes

Maria Luiza Caramori, Luis Henrique Canani, Luciana A. Costa, and Jorge Luiz Gross

From the Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil


   ABSTRACT
TOP
 ABSTRACT
RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The peroxisome proliferator-activated receptor {gamma}2 (PPAR{gamma}2) Pro12Ala polymorphism has been associated with a decreased risk of type 2 diabetes and a lower albumin excretion rate (AER) in patients with established diabetes. We performed a case-control study aiming to evaluate the association between the Pro12Ala polymorphism and diabetic nephropathy. Genomic DNA was obtained from 104 type 2 diabetic patients (case subjects) with chronic renal insufficiency (78 on dialysis and 26 with proteinuria [AER >=200 µg/min] and serum creatinine >=2.0 mg/dl) and 212 normoalbuminuric patients (AER <20 µg/min) with known diabetes duration >=10 years (control subjects). The genotypic distribution of the PPAR{gamma}2 Pro12Ala polymorphism in these diabetic patients was in Hardy-Weinberg equilibrium, and the Ala allele frequency was 9%. The frequency of Ala carriers (Ala/Ala or Ala/Pro) was 20.3% in control subjects and 10.6% in case subjects (P = 0.031). The odds ratio of having diabetic nephropathy for Ala carriers was 0.465 (95% CI 0.229–0.945; P = 0.034). Carriers of the Ala allele were not different from noncarriers (Pro/Pro) regarding sex (38.9 vs. 44.1% males) or ethnicity (77.4 vs. 71.7% white) distribution, age (61 ± 10 vs. 61 ± 10 years), known diabetes duration (17 ± 7 vs. 16 ± 7 years), BMI (27 ± 4 vs. 28 ± 5 kg/m2), fasting plasma glucose (184 ± 81 vs. 176 ± 72 mg/dl), HbA1c (6.7 ± 2.3 vs. 6.9 ± 2.4%; high-performance liquid chromatography reference range: 2.7–4.3%), and systolic (145 ± 27 vs. 0.144 ± 24 mmHg) or diastolic (87 ± 14 vs. 85 ± 14 mmHg) blood pressure, respectively. In conclusion, the presence of the Ala allele may confer protection from diabetic nephropathy in patients with type 2 diabetes.

Diabetic nephropathy is the main cause of end-stage renal disease (ESRD) in the U.S. (1) and western Europe (2) and is responsible for almost half of new ESRD cases. About 80% of these ESRD patients have type 2 diabetes (1,3). It is, therefore, important to identify markers of diabetic nephropathy risk in these patients. A polymorphism in the gene for peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}), a nuclear transcription factor involved in adipocyte differentiation, glucose and lipid metabolism, and fatty acid transport (4), has been associated with decreased risk of type 2 diabetes (5,6) and with lower albumin excretion rate (AER) in patients with established type 2 diabetes (7). Here, we evaluated the association between PPAR{gamma}2 Pro12Ala polymorphism and diabetic nephropathy in patients with type 2 diabetes.


   RESEARCH DESIGN AND METHODS
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
A case-control study was conducted in 316 patients with type 2 diabetes (according to World Health Organization criteria) (8) who were selected from a sample of >1,200 patients participating in a multicenter research protocol in the Rio Grande do Sul state (Brazil). The aim was to identify the genetic and nongenetic risk factors associated with diabetes complications. All type 2 diabetic patients with proteinuria (AER >200 µg/min) and serum creatinine >2.0 mg/dl and all patients with normoalbuminuria (AER <20 µg/min) and known diabetes duration of at least 10 years were studied. The 104 proteinuric patients with serum creatinine >2.0 mg/dl (78 on dialysis) were defined as case subjects, and the 212 normoalbuminuric patients with a known diabetes duration of at least 10 years were defined as control subjects.

This study was approved by the ethics committee of the Hospital de Clínicas de Porto Alegre and the corresponding committees at the institutions from which DNA samples were obtained. Written informed consent was obtained from all participants.

Patients underwent a standardized clinical and laboratory evaluation that, to summarize, consisted of a questionnaire, physical examination, and blood collection. Sitting blood pressure was measured twice to the nearest 2 mmHg after a 5-min rest using a standard mercury sphygmomanometer (phases I and V of Korotkoff). The mean value of three measurements was used to calculate systolic and diastolic blood pressure. Hypertension was defined as blood pressure levels >=140/90 mmHg (9) or the use of antihypertensive medication. Retinopathy was assessed by ophthalmoscopic examination through dilated pupils in 293 patients and classified as absent, nonproliferative, or proliferative. AER was measured in 24-h timed sterile urine samples by immunoturbidimetry (Sera-Pak immuno microalbuminuria; Bayer, Tarrytown, NY). AER values >=200 µg/min were confirmed in a second urine sample. Glucose was measured by the glucose oxidase method, HbA1c by an ion exchange high-performance liquid chromatography (Merck-Hitachi L-9100 GhB analyzer, reference range 2.7–4.3; Merck, Darmstadt, Germany) and serum creatinine by Jaffé’s reaction.

Genotyping.
Genomic DNA was extracted from peripheral blood. The PPAR{gamma}2 Pro12Ala polymorphism was detected as described elsewhere (10). The PCR products were digested overnight at 37°C with BstU-1 enzyme, electrophoresed on a 2.5% agarose gel, and stained with ethidium bromide. The expected products after digestion were 270 bp for normal homozygous (Pro/Pro), 227 bp and 43 bp for Pro12Ala homozygous (Ala/Ala), and 270 bp, 227 bp, and 43 bp for heterozygous (Pro/Ala). The frequency of the Ala allele was 10.0% in white and 7.5% in nonwhite volunteer blood donors (P = 0.357).

Statistical analysis.
The clinical and laboratory characteristics of the case and control subjects were compared by unpaired Student’s t test or {chi}2 test, as appropriate. Genotype distribution in the case and control subjects was compared by {chi}2 test. Multiple logistic regression analysis was used to determine the independent factors associated with diabetic nephropathy. Data are expressed as mean ± SD or as number of patients with a given characteristic. Triglycerides, not normally distributed, were logarithmically transformed before analysis and are presented as median and range. The test for Hardy-Weinberg equilibrium was performed as previously described (11). P values <0.05 were considered significant. SPSS version 10.0 (SPSS, Chicago, IL) was used for the analyses.


   RESULTS
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Patients with diabetic nephropathy (case subjects) were more often men (P < 0.0001) and, as expected, more often hypertensive (P < 0.0001) than long-standing normoalbuminuric patients (control subjects) (Table 1). There was no difference in the proportion of patients using antihypertensive drugs between case (72.9%) and control (64.3%; P = 0.241) subjects. However, case subjects used ACE inhibitors or angiotensin receptor blockers more often (47.2%) than control subjects (29.2%; P = 0.013). Diabetic retinopathy was also more frequent in case (88% with any retinopathy, 72% with proliferative retinopathy) than in control (42% with any retinopathy, 7% with proliferative retinopathy; P < 0.001) subjects. Diabetes treatment in case and control subjects consisted of diet (16.9 vs. 3.2%), oral agents (16.9 vs. 55.2%), or insulin (66.2 vs. 41.6%; P < 0.001), respectively. None of the patients included in this study were using thiazolidonedione compounds.


View this table:
[in this window]
[in a new window]
  		TABLE 1 Clinical and laboratory characteristics of type 2 diabetic patients with normoalbuminuria (control subjects) or with diabetic nephropathy (case subjects)

 
The genotypic distribution of the PPAR{gamma}2 Pro12Ala gene polymorphism was in Hardy-Weinberg equilibrium. The frequency of the Ala allele in these type 2 diabetic patients was 9%. The frequency of Ala carriers (Ala/Ala and Pro/Ala) was higher among normoalbuminuric (20.3%) than diabetic nephropathy (10.6%; P = 0.031) patients. The Ala allele was also more frequent in control subjects (10.8%) than in diabetic nephropathy case subjects (5.8%; P = 0.038). There was no difference in the Ala allele frequency between patients with chronic renal insufficiency (11.5%) and patients on dialysis (10.3%). The odds ratio (OR) of having diabetic nephropathy for Ala allele carriers was 0.465 compared with noncarriers (95% CI 0.229–0.945; P = 0.034). Multiple logistic regression analysis showed that Ala carriers (OR 0.425 [95% CI 0.196–0.974]; P = 0.043) and male sex (3.94 [2.30–6.76]; P < 0.001) were independently associated with diabetic nephropathy. These results did not change when normoalbuminuric patients using ACE inhibitors or angiotensin receptor blockers or nonwhite patients were excluded from the analyses.

There were no differences between Ala carriers and noncarriers regarding age, diabetes duration, sex distribution, BMI, waist-to-hip ratio, fasting plasma glucose, HbA1c, total cholesterol, triglycerides, serum creatinine, and blood pressure levels (Table 2). Also, there was no difference regarding antihypertensive use (63.3 vs. 68.8%; P = 0.558) or ACE inhibitor or angiotensin receptor blocker use (29.4 vs. 37.7%; P = 0.361) between Ala carriers and noncarriers, respectively. There was no difference in the antihyperglycemic regimen used by Ala carriers (10.3% diet, 51.3% oral agents, and 38.5% insulin) or noncarriers (7.3% diet, 40.6% oral agents, and 52.1% insulin; P = 0.295).


View this table:
[in this window]
[in a new window]
  		TABLE 2 Clinical and laboratory characteristics of type 2 diabetic patients according to the presence (Ala/Ala and Pro/Ala) or not (Pro/Pro) of the Ala allele

 

   DISCUSSION
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The decreased risk of diabetic nephropathy among PPAR{gamma}2 Ala12 allele carriers suggests that this genetic variation in PPAR{gamma}2 has a protective role in relation to the risk of diabetic nephropathy in patients with type 2 diabetes. This confirms and extends the observations that Caucasian type 2 diabetic PPAR{gamma}2 Pro12Ala carriers have lower AER levels (7) and, presumably, lower diabetic nephropathy risk. Although no difference in the frequency of Ala allele carriers was observed between normoalbuminuric and ESRD patients (7), this latter study was underpowered to detect this association because only a small number of ESRD patients (n = 44) were evaluated. Further, some of the normoalbuminuric patients may have had a short diabetes duration (interquartile diabetes duration ranging from 4 to 17 years) (7) and may, in fact, be at risk of progressing to diabetic nephropathy (12). The association between the PPAR{gamma}2 Pro12Ala polymorphism and macroalbuminuria, seen only when patients with diabetes duration >=20 years were analyzed (7), is in agreement with this thesis. A large study of Japanese type 2 diabetic patients did not find association between diabetic nephropathy and the PPAR{gamma}2 Pro12Ala polymorphism (13). However, diabetic nephropathy in this study (13) was defined as an AER >10 µg/ml. This could have led to patients with clinically insignificant diabetic renal involvement being included in the diabetic nephropathy group (13).

The mechanisms by which the PPAR{gamma}2 Pro12Ala polymorphism could lead to diabetic nephropathy are unknown. The PPAR{gamma}2 Pro12Ala polymorphism has been associated with higher insulin sensitivity (5,14) and decreased risk of type 2 diabetes (6,10,13–17). Since insulin resistance may be a risk factor for diabetic nephropathy in type 2 diabetes (18,19), improved insulin sensitivity could be the link between the PPAR{gamma}2 Pro12Ala polymorphism and decreased risk of diabetic nephropathy. It would also be reasonable to hypothesize that the diabetic nephropathy protective effect of the PPAR{gamma}2 Pro12Ala polymorphism could be dependent on a decreased risk of hypertension among Ala carriers versus noncarriers. However, there was no difference in the frequency of hypertension between Ala carriers and noncarriers in the current study. Another possibility would be that this polymorphism could modulate the harmful effects of hypertension in the kidney by altering, for example, the expression of plasminogen activator inhibitor 1 and transforming growth factor-ß.

However, caution needs to be exercised when interpreting the results of the present study because association studies require special attention in their design (20,21). It is particularly important to have an appropriate sample size, allowing the detection of true differences between groups, and to adopt strict selection criteria in order to include in the study only patients with well-defined phenotypes (20). In this regard, the current study evaluated a large sample of carefully characterized type 2 diabetic patients, selecting as control subjects only normoalbuminuric patients with a long diabetes duration and as case subjects only patients with clearly established diabetic nephropathy. A possible limitation of the current report would be the inclusion of some patients in the normoalbuminuric group who were, in fact, microalbuminuric patients that had their AER reduced by the use of ACE inhibitors or angiotensin receptor blockers. Nonetheless, as argued above, the association between PPAR{gamma}2 Pro12Ala polymorphism and diabetes complications risk seems to make biological sense. Moreover, this association has been previously reported by Herrmann et al. (7) in a study that found lower AER levels among Ala carriers in a large sample of Caucasian type 2 diabetic patients, indicating a protective effect of the Ala12 allele in relation to diabetic nephropathy.

In conclusion, the presence of the Ala allele of the PPAR{gamma}2 Pro12Ala polymorphism is associated with a decreased risk of diabetic nephropathy in patients with type 2 diabetes. This association needs to be confirmed in other patient populations. More basic studies will be required to uncover the molecular mechanisms underlying the association between PPAR{gamma}2 Pro12Ala polymorphism and diabetic nephropathy risk.


   ACKNOWLEDGMENTS
 
This work was partially supported by grants from Projeto de Núcleo de Excelência do Ministério de Ciência e Tecnologia and Hospital de Clínicas de Porto Alegre. L.A.C. was a recipient of a scholarship from Fundação Coordenação de Aperfeiçoamento de Pessoal de Ensino Superior.

We thank Paula Eichler and Emanuele Kuhn for technical support and Professor Michael Mauer for his thoughtful comments.

Address correspondence and reprint requests to Jorge Luiz Gross, MD, Endocrine Division, Hospital de Clínicas de Porto Alegre, Ramiro Barcellos 2350, Prédio 12, 4° Andar, Porto Alegre, RS, Brazil 90035-003. E-mail: jorgegross{at}terra.com.br

Received for publication April 29, 2003 and accepted in revised form September 8, 2003

Abbreviations: AER, albumin excretion rate; ESRD, end-stage renal disease; PPAR{gamma}, peroxisome proliferator-activated receptor {gamma}


   REFERENCES
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. US Renal Data System: U.S. Renal Data System: 1999 Annual Report. Bethesda, MD, National Institute of Diabetes and Digestive and Kidney Diseases,1999
  2. Rychlik I, Miltenberger-Miltenyi G, Ritz E: The drama of the continuous increase in end-stage renal failure in patients with type II diabetes mellitus. Nephrol Dial Transplant13 :6 –10,1998[Free Full Text]
  3. Bruno RM, Gross JL: Prognostic factors in Brazilian diabetic patients starting dialysis: a 3.6-year follow-up study. J Diabetes Complications14 :266 –271,2000[Medline]
  4. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem39 :665 –668,1996[Medline]
  5. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet20 :284 –287,1998[Medline]
  6. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES: The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet26 :76 –80,2000[Medline]
  7. Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E: Peroxisome proliferator-activated receptor-{gamma}2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: the Berlin Diabetes Mellitus (BeDiaM) study. Diabetes51 :2653 –2657,2002[Abstract/Free Full Text]
  8. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care26 (Suppl. 1) :S5 –S20,2003
  9. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med157 :2413 –2446,1997[Abstract]
  10. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR: Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun241 :270 –274,1997[Medline]
  11. Weir BS: Genetic Data Analysis II. Boston, MA, Sinauer Associates,1996
  12. Caramori ML, Fioretto P, Mauer M: The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes49 :1399 –1408,2000[Abstract]
  13. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, Seino Y, Yasuda K, Hanafusa T, Yamagata K, Awata T, Kadowaki T, Hara K, Yamada N, Gotoda T, Iwasaki N, Iwamoto Y, Sanke T, Nanjo K, Oka Y, Matsutani A, Maeda E, Kasuga M: The Pro12->Ala substitution in PPAR-{gamma} is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes50 :891 –894,2001[Abstract/Free Full Text]
  14. Poulsen P, Andersen G, Fenger M, Hansen T, Echwald SM, Volund A, Beck-Nielsen H, Pedersen O, Vaag A: Impact of two common polymorphisms in the PPAR-{gamma} gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: thrifty genotype, thrifty phenotype, or both? Diabetes52 :194 –198,2003[Abstract/Free Full Text]
  15. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C, Kadowaki T: The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun271 :212 –216,2000[Medline]
  16. Ardlie KG, Lunetta KL, Seielstad M: Testing for population subdivision and association in four case-control studies. Am J Hum Genet71 :304 –311,2002[Medline]
  17. Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, Mohlke KL, Valle TT, Ehnholm C, Buchanan TA, Bergman RN, Collins FS, Boehnke M, Tuomilehto J: The peroxisome proliferator-activated receptor-{gamma}2 Pro12A1a variant: association with type 2 diabetes and trait differences. Diabetes50 :886 –890,2001[Abstract/Free Full Text]
  18. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L: The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia44 :1148 –1154,2001[Medline]
  19. Orchard TJ, Chang YF, Ferrell RE, Petro N, Ellis DE: Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int62 :963 –970,2002[Medline]
  20. Freely associating. Nat Genet22 :1 –2,1999[Medline]
  21. Hirschhorn JN, Altshuler D: Once and again: issues surrounding replication in genetic association studies. J Endocrinol Metab87 :4438 –4441,2002[Free Full Text]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
K. G. Ewens, R. A. George, K. Sharma, F. N. Ziyadeh, and R. S. Spielman
Assessment of 115 Candidate Genes for Diabetic Nephropathy by Transmission/Disequilibrium Test
Diabetes, November 1, 2005; 54(11): 3305 - 3318.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. De Cosmo, A. Marucci, E. Ciociola, R. Di Paola, L. Pucci, G. Penno, S. Del Prato, G. P. Piras, R. Trevisan, S. Giunti, et al.
Lack of evidence for the 1484insG variant at the 3'-UTR of the protein tyrosine phosphatase 1B (PTP1B) gene as a genetic determinant of diabetic nephropathy development in type 1 diabetic patients
Nephrol. Dial. Transplant., September 1, 2004; 19(9): 2419 - 2420.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. C. Florez
Phenotypic Consequences of the Peroxisome Proliferator-Activated Receptor-{gamma} Pro12Ala Polymorphism: The Weight of the Evidence in Genetic Association Studies
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4234 - 4237.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caramori, M. L.
Right arrow Articles by Gross, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caramori, M. L.
Right arrow Articles by Gross, J. L.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum